Company Description
BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China.
It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient.
The company also provides licorice products, such as Gan Di Xin, a medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions.
In addition, it offers traditional Chinese medicine derivatives products comprising Ahan antibacterial paste that is used to treat refractory chronic skin diseases; heparin products, including heparin sodium preparation, an ingredient for pharmaceutical companies to produce medications used in treating cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings, such as Zhu Xiaochang sausage casings for culinary purposes.
Further, the company provides Fertilizer products comprising Xiongguan organic fertilizers to improve crop yield, increase soil’s chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers for plant growth.
BGM Group Ltd. is based in Chengdu, China.
| Country | China |
| Founded | 2019 |
| IPO Date | Jan 12, 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 298 |
| CEO | Chen Xin |
Contact Details
Address: No. 152 Hongliang East 1st Street, No. 1703, Tianfu New District Chengdu, 610200 China | |
| Phone | 86 28 6477 5180 |
| Website | bgmgroupltd.com |
Stock Details
| Ticker Symbol | BGM |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001779578 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Chen Xin | Chief Executive Officer |
| Zhanchang Xin | Chairman of the Board, President, Chief Operating Officer and Chief Scientific Officer |
| Yaxuan Zhai | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 7, 2025 | 6-K | Report of foreign issuer |
| Jan 6, 2025 | SCHEDULE 13D | Filing |
| Dec 3, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Nov 29, 2024 | 6-K | Report of foreign issuer |
| Nov 29, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 27, 2024 | 6-K | Report of foreign issuer |
| Nov 22, 2024 | EFFECT | Notice of Effectiveness |
| Nov 15, 2024 | UPLOAD | Filing |
| Nov 5, 2024 | F-3 | Filing |
| Oct 22, 2024 | 6-K | Report of foreign issuer |